Journal publications

Export 68 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
2013
Castro H, Pillay D, Cane P A, Asboe D, Cambiano V, Phillips A, Dunn D.  2013.  Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 208:1459-63.
Santoro MM, Sabin C, Forbici F., Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Dolling D, Dunn D, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin C, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
Mackie NE, Dunn D, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin C, Geretti A M.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Koning FA, Castro H, Dunn D, Tilston P, Cane P A, Mbisa JL.  2013.  Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.
De Luca A., Dunn D, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Dolling D, Dunn D, Geretti A M, Sabin C.  2013.  HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.
Waters L., Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A.  2013.  Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.
2012
Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A.J, Churchill D, Williams I, Geretti A M et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
Dolling D, Phillips A, Delpech V, Pillay D, Cane P A, Crook A.M, Shepherd J., Fearnhill E, Hill T, Dunn D.  2012.  Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.
Barber TJ, Harrison LJ, Asboe D, Williams I, Kirk S., Gilson R, Bansi L, Pillay D, Dunn D.  2012.  Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.
Castro H, Pillay D, Sabin C, Dunn D.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.
Donegan K.L, Walker A.S, Dunn D, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM.  2012.  The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.
2011
Leigh Brown A.J, Lycett SJ, Weinert L, Hughes GJ, Fearnhill E, Dunn D.  2011.  Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.
Wittkop L., Gunthard H.F, de Wolf F., Dunn D, Cozzi-Lepri A, De Luca A., Kucherer C., Obel N., von Wyl V., Masquelier B. et al..  2011.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.
Bansi L, Smith C, Phillips A, Kirk S., Geretti A M, Johnson M, Mackie NE, Post FA, Gazzard B, Dunn D et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Dunn D, Coughlin K., Cane P A.  2011.  Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.
Prosperi M.C, Mackie NE, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn D, Paredes R., Sabin C, Lundgren J.D, Phillips A, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
2010
Fox J, Castro H, Kaye S, McClure M, Weber JN, Fidler S.  2010.  Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.